CADTH Canadian Drug Expert Committee recommendation : Travoprost 0.003% (Izba -- Novartis Pharmaceuticals Canada inc. on behalf of Alcon Canada Inc.) : indication : for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension / CADTH Canadian Drug Expert Committee.

Format:

Book

Author/Creator:

CADTH Canadian Drug Expert Committee, author.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Drugs--Cost effectiveness.

Drugs.

Open-angle glaucoma.

Physical Description:

1 online resource.

Edition:

First edition.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that travoprost 0.003% preserved with polyquaternium-1 (PQ) be reimbursed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), if the following condition is met: The drug plan cost of treatment with travoprost 0.003% PQ should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA).

Notes:

Description based on publisher supplied metadata and other sources.